BioDtech, Inc. (BDTI) was formed in September 2003 to accelerate the development of technologically advanced products geared toward the endotoxin market. Three key factors differentiate BDTI from other organizations involved in the detection of endotoxin:
Shortly after its founding in 2003, BioDtech conducted extensive marketing research in the existing endotoxin marketplace. We discovered an opportunity existed to develop new technology based on existing patented research (Factor C Peptide Reagent). BDTI negotiated a license agreement with the National University of Singapore (NUS) for the exclusive worldwide licensing rights to develop specific research products and technology as related to endotoxin detection, neutralization and removal.
In addition to this partnership, BDTI has begun to scope out strategic partnerships with other biopharmaceutical, pharmaceutical and medical device companies that could utilize our technology with their existing portfolio of products. In the years ahead, BDTI anticipates that our technology will possibly change forever the way in which infectious disease management is practiced.
View Company Profile
(PDF file, 26 KB)
As a Founder and head of research and development of diagnostic and therapeutic products for the company he is key in the overall management of the business strategy. He has negotiated license options with major universities and has successfully evaluated and further developed products based on patented research discovered for endotoxin detection and development.
Dr. Pepe has extensive R&D experience spanning more than 20 years in a variety of settings including, biotech startup, lab management (both diagnostic and therapeutic), FDA regulatory issues, basic research and IPO. He has first hand experience in successfully taking a biotech venture from start to finish.
As a Founder and executive he has primary responsibility for the financial operation including the contract negotiations, intellectual property transfer, grant development, audit requirements and general operations of the company. He has worked extensively with universities, non-profit foundations and research facilities, pharmaceutical companies and executives at both management and board levels.
Mr. Weiss has extensive biotech/biomedical experience spanning more than 20 years in a variety of settings including, biotech incubation, basic research, clinical research, clinical laboratory, hospital management, laboratory automation and patient billing. He possesses a unique blend of first hand experience combined with extensive finance, legal and operation expertise.